Alzheimer's Drug Examined for Use in Treatment-Resistant Depression
the Psychiatry Advisor take:
Researchers at the University of Texas Southwestern Medical Center are conducting research into using the dementia drug Namenda (memantine) as a therapy for treatment-resistant depression. Memantine, acts on the brain’s NMDA receptors, which are known to play a role in depression. The research could eventually lead to a treatment that blocks NMDA receptors and better controls depression with fewer side effects.
Memantine is chemically similar to ketamine, which is known to produce a fast-acting antidepressant effect in patients. However, ketamine’s other effects and recreational use make it unable to use for depression. But memantine reacts with the same brain receptors as ketamine, though researchers have found that it doesn’t produce the same antidepressant effect.
Identifying Fast-Acting Treatments for Resistant Depression
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Transference in the Age of #MeToo: What Counts as Harassment From a Patient?
- Models Derived From Electronic Health Records Effective in Predicting Suicide Risk
- Autonomic Function May Have Directional Effect on Depression
- Predictors of Long-term Medication Adherence in Children With ADHD
- Probiotics Effective in Reducing Rehospitalization for Patients With Mania
- Court-Mandated Substance Abuse Treatment: Exploring the Ethics and Efficacy
- ADHD Treatments
- Pharmacogenetics in Psychiatry: Promising Developments and Potential Pitfalls
- Esketamine Nasal Spray: A New Treatment Possibility for Treatment-Resistant Depression
- Substance Abuse and Primary Psychosis: A Closer Look